Global Surgical Lasers Market worth 2.37 Billion USD by 2021

IMT News Desk
IMT News Desk
· 2 min read

According to Markets and Markets report “Surgical Lasers Market  Global forecast to 2021″, the market is  expected to reach USD 2.37 Billion by 2021; growing at a CAGR of 5.1% from 2016 to 2021.

Factors driving the growth of this market include technological advancements in surgical lasers, high prevalence of chronic diseases, high prevalence of ophthalmic disorders, and growing preference for minimally invasive surgeries. However, limited medical reimbursements and high procedural costs associated with laser surgeries are expected to limit the optimal growth of this market during the coming years.

On the basis of type, the surgical lasers market is categorized into five segments, namely, carbon dioxide (CO2) lasers, argon lasers, Nd:YAG lasers, diode lasers, and other surgical lasers (fiber lasers, dye lasers, Er:YAG lasers, and excimer lasers).

The carbon dioxide (CO2) lasers segment is growing at the highest CAGR in the market due to the widespread availability of innovative CO2-based surgical lasers and ongoing technological advancements in cosmetic laser treatment.

Based on procedure type, the market is segmented into open surgery, laparoscopic surgery, and percutaneous surgery.

The laparoscopic surgery segment is expected to dominate the market. This growth can be primarily attributed to the procedural benefits of laparoscopic procedures and growing patient awareness and market demand for less-invasive disease therapies.

By application, the market is segmented into ophthalmology, dentistry, dermatology, cardiology, gynecology, urology, oncology, and other applications (liposuction, ENT, and GIT).

The urology segment is expected to be the fastest-growing surgical laser application segment. Growth in this application segment can be attributed to the rising prevalence of urological disorders (such as kidney stones, renal cancer, and prostate enlargement), growing patient preference for minimally invasive urological surgeries, and ongoing technological advancements in surgical laser products.

As of 2015, Lumenis (Israel), Cynosure, Inc. (U.S.), Alma Lasers (Israel), IPG Photonics Corporation (U.S.), Abbott Laboratories, Inc. (U.S.), Boston Scientific Corporation (U.S.), Spectranetics Corporation (U.S.), Biolitec AG (Austria), Fotona d.o.o. (Slovenia), and BISON MEDICAL Co., Ltd. (South Korea) are some of the key players operating in the surgical lasers market.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk